Article

Allergan expands Refresh line with new formula for eye allergies

Allergan Inc. has expanded its artificial tears and eye drops product offerings with the addition of ketotifen fumarate ophthalmic solution (Refresh Eye Itch Relief), an over-the-counter eye drop for patients with itchy eyes due to allergies.

Allergan Inc. has expanded its artificial tears and eye drops product offerings with the addition of ketotifen fumarateophthalmic solution (Refresh Eye Itch Relief), an over-the-counter eye drop for patients with itchy eyes due toallergies.

"[This antihistamine eye drop] offers allergy sufferers quick, sustained relief from itchy eyes with the same efficacy as theoriginal prescription formulation of ketotifen fumarate ophthalmic solution," said Joseph Schultz, Allergan's senior vicepresident of sales and marketing, U.S. Eye Care.

The triple-action formula provides a potent antihistamine effect to offer relief in minutes; mast cell stabilization tosustain relief for up to 12 hours; and eosinophil inhibition to prevent late-phase allergic reaction, said the company in aprepared statement. The company has said the product is safe for adults and children ages 3 and older.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.